274 related articles for article (PubMed ID: 29382747)
1. Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation.
Betts BC; Bastian D; Iamsawat S; Nguyen H; Heinrichs JL; Wu Y; Daenthanasanmak A; Veerapathran A; O'Mahony A; Walton K; Reff J; Horna P; Sagatys EM; Lee MC; Singer J; Chang YJ; Liu C; Pidala J; Anasetti C; Yu XZ
Proc Natl Acad Sci U S A; 2018 Feb; 115(7):1582-1587. PubMed ID: 29382747
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect.
Choi J; Cooper ML; Alahmari B; Ritchey J; Collins L; Holt M; DiPersio JF
PLoS One; 2014; 9(10):e109799. PubMed ID: 25289677
[TBL] [Abstract][Full Text] [Related]
3. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
Fowler DH; Gress RE
Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
[TBL] [Abstract][Full Text] [Related]
4. Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results.
Pidala J; Walton K; Elmariah H; Kim J; Mishra A; Bejanyan N; Nishihori T; Khimani F; Perez L; Faramand RG; Davila ML; Nieder ML; Sagatys EM; Holtan SG; Lawrence NJ; Lawrence HR; Blazar BR; Anasetti C; Sebti SM; Betts BC
Clin Cancer Res; 2021 May; 27(10):2712-2722. PubMed ID: 33753457
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Human Dendritic Cell ER Stress Response Reduces T Cell Alloreactivity Yet Spares Donor Anti-tumor Immunity.
Betts BC; Locke FL; Sagatys EM; Pidala J; Walton K; Menges M; Reff J; Saha A; Djeu JY; Kiluk JV; Lee MC; Kim J; Kang CW; Tang CH; Frieling J; Lynch CC; List A; Rodriguez PC; Blazar BR; Conejo-Garcia JR; Del Valle JR; Hu CC; Anasetti C
Front Immunol; 2018; 9():2887. PubMed ID: 30574153
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-17-92 controls T-cell responses in graft-versus-host disease and leukemia relapse in mice.
Wu Y; Heinrichs J; Bastian D; Fu J; Nguyen H; Schutt S; Liu Y; Jin J; Liu C; Li QJ; Xia C; Yu XZ
Blood; 2015 Sep; 126(11):1314-23. PubMed ID: 26138686
[TBL] [Abstract][Full Text] [Related]
7. Donor T cells administered over HLA class II barriers mediate antitumor immunity without broad off-target toxicity in a NOD/scid mouse model of acute leukemia.
Stevanović S; Nijmeijer BA; van Schie ML; Salvatori DC; Maas S; Griffioen M; Falkenburg JH
Biol Blood Marrow Transplant; 2013 Jun; 19(6):867-75. PubMed ID: 23500532
[TBL] [Abstract][Full Text] [Related]
8. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
[TBL] [Abstract][Full Text] [Related]
9. Graft-vs-leukemia activity and graft-vs-host disease induced by allogeneic Th1- and Th2-type CD4+ T cells in mice.
Zeis M; Uharek L; Hartung G; Glass B; Steinmann J; Schmitz N
Hematol J; 2001; 2(2):136-44. PubMed ID: 11424006
[TBL] [Abstract][Full Text] [Related]
10. Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining Treg and antitumor CTL function.
Betts BC; Veerapathran A; Pidala J; Yang H; Horna P; Walton K; Cubitt CL; Gunawan S; Lawrence HR; Lawrence NJ; Sebti SM; Anasetti C
Sci Transl Med; 2017 Jan; 9(372):. PubMed ID: 28077684
[TBL] [Abstract][Full Text] [Related]
11. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration.
Gao Y; Shan W; Gu T; Zhang J; Wu Y; Li X; Zeng X; Zhou H; Chen Z; Xiao H
Front Immunol; 2021; 12():785774. PubMed ID: 34987512
[TBL] [Abstract][Full Text] [Related]
12. Targeting Sirt-1 controls GVHD by inhibiting T-cell allo-response and promoting Treg stability in mice.
Daenthanasanmak A; Iamsawat S; Chakraborty P; Nguyen HD; Bastian D; Liu C; Mehrotra S; Yu XZ
Blood; 2019 Jan; 133(3):266-279. PubMed ID: 30514750
[TBL] [Abstract][Full Text] [Related]
13. Differential Effect of MyD88 Signal in Donor T Cells on Graft-versus-Leukemia Effect and Graft-versus-Host Disease after Experimental Allogeneic Stem Cell Transplantation.
Lim JY; Ryu DB; Lee SE; Park G; Choi EY; Min CK
Mol Cells; 2015 Nov; 38(11):966-74. PubMed ID: 26552489
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-27 Enforces Regulatory T Cell Functions to Prevent Graft-versus-Host Disease.
Le HT; Keslar K; Nguyen QT; Blazar BR; Hamilton BK; Min B
Front Immunol; 2020; 11():181. PubMed ID: 32117306
[TBL] [Abstract][Full Text] [Related]
15. Absence of inducible costimulator on alloreactive T cells reduces graft versus host disease and induces Th2 deviation.
Hubbard VM; Eng JM; Ramirez-Montagut T; Tjoe KH; Muriglan SJ; Kochman AA; Terwey TH; Willis LM; Schiro R; Heller G; Murphy GF; Liu C; Alpdogan O; van den Brink MR
Blood; 2005 Nov; 106(9):3285-92. PubMed ID: 15956289
[TBL] [Abstract][Full Text] [Related]
16. Selective NFAT targeting in T cells ameliorates GvHD while maintaining antitumor activity.
Vaeth M; Bäuerlein CA; Pusch T; Findeis J; Chopra M; Mottok A; Rosenwald A; Beilhack A; Berberich-Siebelt F
Proc Natl Acad Sci U S A; 2015 Jan; 112(4):1125-30. PubMed ID: 25583478
[TBL] [Abstract][Full Text] [Related]
17. Tolerogenic anti-IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity.
Song Q; Wang X; Wu X; Qin H; Li Y; Riggs AD; Martin PJ; Chen YZ; Zeng D
Blood; 2021 Apr; 137(16):2243-2255. PubMed ID: 33511398
[TBL] [Abstract][Full Text] [Related]
18. Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) Differentiates GVL and GVHD in Allo-HSCT.
Mammadli M; Huang W; Harris R; Sultana A; Cheng Y; Tong W; Pu J; Gentile T; Dsouza S; Yang Q; Bah A; August A; Karimi M
Front Immunol; 2020; 11():593863. PubMed ID: 33324410
[TBL] [Abstract][Full Text] [Related]
19. Paradoxical effects of IFN-gamma in graft-versus-host disease reflect promotion of lymphohematopoietic graft-versus-host reactions and inhibition of epithelial tissue injury.
Wang H; Asavaroengchai W; Yeap BY; Wang MG; Wang S; Sykes M; Yang YG
Blood; 2009 Apr; 113(15):3612-9. PubMed ID: 19211507
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic inhibition of PKCα and PKCθ prevents GVHD while preserving GVL activity in mice.
Haarberg KM; Li J; Heinrichs J; Wang D; Liu C; Bronk CC; Kaosaard K; Owyang AM; Holland S; Masuda E; Tso K; Blazar BR; Anasetti C; Beg AA; Yu XZ
Blood; 2013 Oct; 122(14):2500-11. PubMed ID: 23908466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
